Researchers say commercials targeting men with low moods and sexual drive may be unfounded. The condition--which they call "low T" for testosterone--is the subject of much debate. But The Milwaukee Journal Sentinel reported that the study on the drug AndroGel was funded by the drugmaker. The paper also alleged that the company conspired to make an agreement with generic drug manufacturers that would keep a generic equivalent off the market for six years.
Read full story >